Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluating RB1 and p53 as diagnostic markers in treatment-related neuroendocrine prostate cancer through immunohistochemistry and genomic analysis of RB1 and TP53.

The Prostate - 1 Dec 2024

Ueki Hideto, Jimbo Naoe, Terakawa Tomoaki, Hara Takuto, Tobe Taisuke, Hirata Junichiro, Wakita Naoto, Okamura Yasuyoshi, Suzuki Kotaro, Bando Yukari, Chiba Koji, Teishima Jun, Nakano Yuzo, Miyake Hideaki

Abstract excerpt

BACKGROUND: The diagnosis of treatment-related neuroendocrine prostate cancer (t-NEPC) often involves a pathological assessment and immunohistochemistry (IHC) for neuroendocrine markers. Genomic alterations in RB1 and TP53 are frequently observed in NEPC and are believed to play a crucial role in the transformation of adenocarcinoma to NEPC. In this study, we examined the clinicopathologic, immunohistochemical,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Neuroendocrine

Share to Immunohistochemistry

Share to Prostatic Neoplasms

Share to Retinoblastoma Binding Proteins

Share to Tumor Suppressor Protein p53

Share to Ubiquitin-Protein Ligases

Source

Identifiers

PMID: 39279246
DOI: 10.1002/pros.24791

Genes

RB1
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluating RB1 and p53 as diagnostic markers in treatment-related neuroendocrine prostate cancer through immunohistochemistry and genomic analysis of RB1 and TP53.PMID 39279246Read ↗

Real-world experience in treatment outcome and genomic insights for metastatic prostate neuroendocrine carcinoma.Semantic proximity Read ↗

Treatment-related Neuroendocrine Prostate Carcinoma—Diagnostic and Molecular CorrelatesSemantic proximity Read ↗

Role of MicroRNAs in Neuroendocrine Prostate CancerSemantic proximity Read ↗

The utility of next-generation sequencing in metastatic prostate cancer FNA biopsies.Semantic proximity Read ↗

Treatment-induced neuroendocrine prostate cancer and de novo neuroendocrine prostate cancer: Identification, prognosis and survival, genetic and epigenetic factorsSemantic proximity Read ↗

Clinicopathological and Genetic Analyses of Small Cell Neuroendocrine Carcinoma of the Prostate: Histological Features for Accurate Diagnosis and Toward Future Novel Therapies Short Running Title: Characteristics of Prostatic Small Cell Neuroendocrine CarcinomaSemantic proximity Read ↗

Neuroendocrine Prostate Cancer: Subtypes, Biology, and Clinical OutcomesSemantic proximity Read ↗

Integrated analysis of single-cell and bulk transcriptomics develops a robust neuroendocrine cell-intrinsic signature to predict prostate cancer progressionSemantic proximity Read ↗

Unmasking Neuroendocrine Prostate Cancer with a Machine Learning-Driven 7-Gene Stemness Signature that Predicts ProgressionSemantic proximity Read ↗

Distinct prostate cancer neuroendocrine subtypes predict prognosis and guide personalized prostate-specific membrane antigen-targeted therapySemantic proximity Read ↗

[Neuroendocrine prostate cancer: Natural history, molecular features, therapeutic management and future directions].Semantic proximity Read ↗

Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug TargetsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.